Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $4.40
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 18, 26 |
Daily · Wilder smoothing
| Cantor Fitzgerald |
| maintain |
| Overweight |
| Overweight |
| Aug 14, 26 | Oppenheimer | maintain | Outperform | Outperform |
| May 28, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 19, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 10, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 13, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 18, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 15, 25 | Oppenheimer | maintain | Outperform | Outperform |
| Jul 16, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 33.33 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 20.45 | Oscillator | Neutral |
| Williams %R (14) | -86.36 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.30 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 32.76 (+DI 15.4 / -DI 30.6) | Trend | Strong Sell |
| EMA 20 | 4.79 | MA | Strong Sell |
| SMA 20 | 4.80 | MA | Strong Sell |
| EMA 50 | 5.27 | MA | Strong Sell |
| SMA 50 | 5.40 | MA | Strong Sell |
| SMA 200 | 5.51 | MA | Strong Sell |
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 29, 26 | Seshadri Vishwas | director, officer: Chief Executive Officer | S-Sale | 19,608 @ $5.16 | $101.1K |
| Sep 29, 26 | Vazzano Joseph Walter | officer: Chief Financial Officer | S-Sale | 9,191 @ $5.16 | $47.39K |
| Sep 29, 26 | O'Malley Brendan M. | officer: SVP, Chief Legal Officer | S-Sale | 6,727 @ $5.16 | $34.68K |
| Sep 29, 26 | Vasanthavada Madhav | officer: Chief Commercial Officer | S-Sale | 4,902 @ $5.16 | $25.27K |
| Sep 1, 26 | Alvino Mark | director | S-Sale | 15,000 @ $5.86 | $87.97K |
| Jul 21, 26 | Vazzano Joseph Walter | officer: Chief Financial Officer | S-Sale | 1,478 @ $6.53 | $9.65K |
| Jul 9, 26 | Vazzano Joseph Walter | officer: Chief Financial Officer | S-Sale | 24,880 @ $6.96 | $173.3K |
| Jul 9, 26 | Seshadri Vishwas | director, officer: Chief Executive Officer | S-Sale | 67,971 @ $6.96 | $473.3K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13D | Oct 23, 2026 | 2026-10-23 14:38:24 | View |
| 4 | Sep 29, 2026 | 2026-09-29 21:48:44 | View |
| 4 | Sep 29, 2026 | 2026-09-29 21:48:36 | View |
| 4 | Sep 29, 2026 | 2026-09-29 21:48:06 | View |
| 4 | Sep 29, 2026 | 2026-09-29 21:47:40 | View |
| 8-K | Sep 15, 2026 | 2026-09-15 12:00:17 | View |
| 4 | Sep 1, 2026 | 2026-09-01 17:48:45 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:25:23 | View |
| 10-Q | Aug 13, 2026 | 2026-08-13 07:30:38 | View |
| 8-K | Aug 13, 2026 | 2026-08-13 07:30:14 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Abeona Therapeutics NASDAQ: ABEO highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.23 | -0.35 | Miss -51.1% | $11.38M |
| May 13, 2026 | -0.33 | -0.30 | Beat 9.1% | $8.72M |
| Mar 17, 2026 | -0.35 | -0.34 | Beat 2.9% | $5.40M |
| Nov 12, 2025 | -0.27 | -0.10 | Beat 63.0% | — |
| Aug 11, 2025 | -0.39 | 1.71 | Beat 538.5% | $400.0K |
| May 14, 2025 | -0.35 | -0.24 | Beat 31.4% | — |
TTM vs. 5-year historical average (annual ratios)
| Metric | ABEO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -3.9x | -0.5x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -4.5x | EPS est. -0.97 | Elevated |
| Price / Book | 2.0x | 3.2x | Discount |
| Price / Sales | 9.9x | 21.4x | Discount |
| EV / EBITDA | -3.0x | -0.7x | Elevated |
| Return on equity | -41.7% | — | Weak |
| Gross margin | 56.6% | 59.2% | In line |
| Debt / Equity | 0.16 | 0.31 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -3.51 | Distress |
Discounted cash flow model